Homburger advises Novartis in the sale of a sterile drug product fill & finish facility to Lonza
On July 1, 2019, it was announced that Novartis (SIX: NOVN) and Lonza (SIX: LONN) entered into a binding contractual commitment for the sale of a sterile drug product fill & finish facility of Novartis in Stein (Canton of Aargau) to Lonza. The management and operations teams will be retained and Lonza will manufacture for Novartis at the facility.
Homburger advises Novartis in this matter. The Homburger team is led by partner Marcel Dietrich (Real Estate) and includes counsel Peter Müller (Tax), associates Daniel Häusermann, Daniel Kuhn and Aron Waltuch (all Corporate / M&A), Luca Dal Molin (IP / IT), Stefan Gäumann (Real Estate), as well as junior associates Michael Lüchinger and Oriana Schöni (both Corporate / M&A). Associates Stefan Blunschi (Corporate / M&A), Irène Suter-Sieber and Jakob Steiner (both Employment and Executive Compensation) also contributed to the transaction.